Open Label Study of TRx0014 in Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-13

Study Completion Date

2010-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

NCT00515333

Dementia, Alzheimer Type

COMPLETED PHASE2

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01689246

Alzheimer's Disease

COMPLETED PHASE3

Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

NCT03446001

Alzheimer Disease

COMPLETED PHASE3

Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease

NCT01626391

Alzheimer's Disease

TERMINATED PHASE2

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805

Alzheimer's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

30mg tid TRx0014

Group Type ACTIVE_COMPARATOR

TRx0014

Intervention Type DRUG

Gelatin capsule, tid

2

60mg tid TRx0014

Group Type ACTIVE_COMPARATOR

TRx0014

Intervention Type DRUG

Gelatin capsule, tid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TRx0014

Gelatin capsule, tid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments. The carer must provide written consent to his or her own participation in the study.
* Patients with capacity must give written informed consent to participate in this study. Patients who lack capacity to consent must be in agreement with entering into the study and have a personal legal representative giving written informed consent to their participation.
* The patient must have been ongoing in TRx-014-001 at time of study termination.

Eligible Sex

ALL

Accepts Healthy Volunteers

No